Curesponse has developed a 3-dimensional tissue culture system for modeling cancer growth and drug response. The platform, preserves the cancer tissue architecture (including vasculature and immune system) accurately reflecting the cancer growth found in the body.
Employees: 11-50
Total raised: $14M
Founded date: 2017
Investors 3
Funding Rounds 2
| Date | Series | Amount | Investors |
| 15.11.2021 | - | $8M | - |
| 05.06.2020 | Series A | $6M | - |
Mentions in press and media 5
| Date | Title | Description |
| 17.11.2021 | Curesponse Secures Additional USD 8 Million Funding for Its Breakthrough Precision Oncology Platform | REẖOVOT, Israel, November 15, 2021 (Newswire.com) – Curesponse (www.curesponse.com) has secured additional USD 8 million funding for its breakthrough precision oncology platform. Curesponse is a cancer precision medicine company whose plat... |
| 15.11.2021 | Curesponse Secures Additional USD 8 Million Funding for Its Breakthrough Precision Oncology Platform | REẖOVOT, Israel, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Curesponse (www.curesponse.com) has secured additional USD 8 million funding for its breakthrough precision oncology platform. Curesponse is a cancer precision medicine company whose platfo... |
| 15.11.2021 | Curesponse Secures Additional USD 8 Million Funding for Its Breakthrough Precision Oncology Platform | REẖOVOT, Israel, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Curesponse (www.curesponse.com) has secured additional USD 8 million funding for its breakthrough precision oncology platform. Curesponse is a cancer precision medicine company whose platfo... |
| 30.06.2020 | ‘Covid Put Everything On Steroids,’ Says Prominent Healthtech Investor | When VC aMoon was established in 2017, “the premise was to invest heavily in the convergence of technology and biology, healthcare and data,” says Dr. Yair Schindel, its Managing Partner. Schindel and Marius Nacht, the other founder of the ... |
| 05.06.2020 | Curesponse Secures $6M Series A for Breakthrough Precision Medicine | - |